Pages that link to "Q28324069"
Jump to navigation
Jump to search
The following pages link to Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro (Q28324069):
Displaying 50 items.
- Pathogenesis of human immunodeficiency virus infection (Q24634681) (← links)
- Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1 (Q24673555) (← links)
- Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro (Q28326720) (← links)
- Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy (Q28367526) (← links)
- Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase (Q28367547) (← links)
- Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro (Q28367552) (← links)
- pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo (Q28368048) (← links)
- Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues (Q28377244) (← links)
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. (Q28378727) (← links)
- Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication (Q28378991) (← links)
- Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro (Q28379173) (← links)
- In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates (Q28379223) (← links)
- Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D( ) nucleoside analogs in vitro (Q28379621) (← links)
- Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection (Q30400060) (← links)
- Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5 (Q33647608) (← links)
- N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations (Q33869951) (← links)
- Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus (Q33981009) (← links)
- The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates (Q34091824) (← links)
- Zidovudine therapy in HIV infection: which patients should be treated and when (Q34347587) (← links)
- Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing (Q34742873) (← links)
- Evaluation of drug resistance in HIV infection (Q34805974) (← links)
- Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. (Q35122064) (← links)
- Viruses, chemotherapy and immunity (Q35172760) (← links)
- Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy (Q35232016) (← links)
- Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection (Q35331251) (← links)
- Antiviral therapy for human immunodeficiency virus infections (Q35366050) (← links)
- Antiretroviral therapy for patients with HIV disease (Q35802185) (← links)
- Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro (Q35836636) (← links)
- Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. (Q35839770) (← links)
- AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? (Q36893107) (← links)
- Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates (Q36944912) (← links)
- Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus (Q38511971) (← links)
- Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors (Q39454698) (← links)
- In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure (Q39463811) (← links)
- The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study (Q39852169) (← links)
- Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. (Q39873967) (← links)
- In vitro evaluation of experimental agents for anti-HIV activity (Q39989119) (← links)
- Synthesis of some novel substituted purine derivatives as potential anticancer, anti-HIV-1 and antimicrobial agents (Q40160560) (← links)
- Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro (Q40285439) (← links)
- HIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring (Q40393212) (← links)
- Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy (Q40491653) (← links)
- Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice (Q40884087) (← links)
- Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences (Q40931968) (← links)
- Detection of squirrel monkey retroviral sequences in interferon samples (Q41048360) (← links)
- Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. (Q41501389) (← links)
- Chemotherapeutic Options in HIV Infection (Q41505879) (← links)
- Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients (Q41898084) (← links)
- The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro (Q42932779) (← links)
- Antiviral activity of meliacine on the replication of a thymidine kinase-deficient mutant of Herpes simplex virus type 1 alone and in combination with acyclovir (Q45393862) (← links)
- A rapid, direct test for zidovudine susceptibility in clinical isolates of human immunodeficiency virus type 1 (HIV-1) from infected children (Q45545103) (← links)